A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Mar 3, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called Tumor-Treating Fields (TTFields) using a device called the NovoTTF-200T System for people with lung adenocarcinoma, which is a type of lung cancer. The goal is to see if this treatment is safe and practical to use before surgery to remove the cancer. Researchers are also interested in how TTFields might help the body’s immune system fight the cancer.

To be eligible for this study, participants need to be at least 22 years old and have a specific type of lung adenocarcinoma that is suitable for surgical removal. They should have a lung nodule larger than 1 cm that is suspected to be cancer and be planning to have a biopsy. This trial is open to anyone regardless of gender, and it is currently recruiting participants. If you decide to join, you will receive the TTFields treatment and be monitored closely to ensure your safety and to gather information on how well the treatment works.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The participant (or legally acceptable representative \[LAR\], if applicable) provides written informed consent for the study.
• • The participant is ≥22 years of age on the day of signing informed consent.
• • The participant has clinical stage 1A2, 1A3 or IB biopsy-proven lung ADC and is eligible for anatomical resection.
• • The participant has a lung nodule \>1 cm and suspected lung ADC with a plan to undergo biopsy.
• • The participant with multiple nodules has one nodule that meets the criteria.
• • The participant has no history of prior malignancy in the chest or has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy.
• Exclusion Criteria:
• • Patients receiving therapy for concurrent active malignancy
• • Patients with a history of cardiac arrhythmias and/or pacemaker use
• • Patients with lung nodules \<1cm
• • Patients with lung nodules that are pure ground glass opacities (GGOs) of any size
• • Patients with lung nodules that are \<50% solid of any size